Safety of megadose meropenem in the empirical treatment of nosocomial sepsis : a pilot randomized clinical trial
Objective: To evaluate the safety of megadose meropenem as empirical treatment of nosocomial sepsis. Materials & methods: Critically ill patients diagnosed with sepsis received either high-dose (2 g every 8 h) or megadose (4 g every 8 h) meropenem as an intravenous infusion over 3 h. Results: A total of 23 patients with nosocomial sepsis were eligible and included in the megadose (n = 11) or high-dose (n = 12) group. No treatment-related adverse events were observed during a 14-day follow-up. Clinical response was also comparable between the groups. Conclusion: Megadose meropenem may be considered for empirical treatment of nosocomial sepsis without serious concern regarding its safety.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Future microbiology - 18(2023) vom: 28. Apr., Seite 335-342 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salehi, Mohammadreza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 22.05.2023 Date Revised 24.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fmb-2022-0170 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356435482 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356435482 | ||
| 003 | DE-627 | ||
| 005 | 20231226070445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fmb-2022-0170 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356435482 | ||
| 035 | |a (NLM)37140270 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salehi, Mohammadreza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of megadose meropenem in the empirical treatment of nosocomial sepsis |b a pilot randomized clinical trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.05.2023 | ||
| 500 | |a Date Revised 24.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: To evaluate the safety of megadose meropenem as empirical treatment of nosocomial sepsis. Materials & methods: Critically ill patients diagnosed with sepsis received either high-dose (2 g every 8 h) or megadose (4 g every 8 h) meropenem as an intravenous infusion over 3 h. Results: A total of 23 patients with nosocomial sepsis were eligible and included in the megadose (n = 11) or high-dose (n = 12) group. No treatment-related adverse events were observed during a 14-day follow-up. Clinical response was also comparable between the groups. Conclusion: Megadose meropenem may be considered for empirical treatment of nosocomial sepsis without serious concern regarding its safety | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a empirical | |
| 650 | 4 | |a high-dose | |
| 650 | 4 | |a megadose | |
| 650 | 4 | |a meropenem | |
| 650 | 4 | |a sepsis | |
| 650 | 7 | |a Meropenem |2 NLM | |
| 650 | 7 | |a FV9J3JU8B1 |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Rezazade-Moayed, Farah |e verfasserin |4 aut | |
| 700 | 1 | |a Khalili, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Hemati, Homa |e verfasserin |4 aut | |
| 700 | 1 | |a Aghdami, Nasser |e verfasserin |4 aut | |
| 700 | 1 | |a Dashtkoohi, Mohadese |e verfasserin |4 aut | |
| 700 | 1 | |a Dashtkoohi, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Beig-Mohammadi, Mohammad-Taghi |e verfasserin |4 aut | |
| 700 | 1 | |a Ramezani, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Hajiabdolbaghi, Mahboobeh |e verfasserin |4 aut | |
| 700 | 1 | |a Fattah-Ghazi, Samrand |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future microbiology |d 2006 |g 18(2023) vom: 28. Apr., Seite 335-342 |w (DE-627)NLM171766504 |x 1746-0921 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g day:28 |g month:04 |g pages:335-342 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fmb-2022-0170 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |b 28 |c 04 |h 335-342 | ||